Recent Investment Analysts’ Ratings Updates for Opus Genetics (IRD)

Several analysts have recently updated their ratings and price targets for Opus Genetics (NASDAQ: IRD):

• 1/28/2026 – Opus Genetics had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
• 1/22/2026 – Opus Genetics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – Opus Genetics is now covered by analysts at BTIG Research. They set a “buy” rating and a $7.00 price target on the stock.
• 1/20/2026 – Opus Genetics is now covered by analysts at BTIG Research. They set a “buy” rating and a $7.00 price target on the stock.
• 1/17/2026 – Opus Genetics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/3/2026 – Opus Genetics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/13/2025 – Opus Genetics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/10/2025 – Opus Genetics is now covered by analysts at B. Riley. They set a “buy” rating and a $9.00 price target on the stock.
• 12/1/2025 – Opus Genetics was upgraded by analysts at Brookline Capital Management to a “strong-buy” rating.

Insider Buying and Selling at Opus Genetics

In related news, Director Fighting Blindness Foundation sold 4,000,000 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $2.15, for a total value of $8,600,000.00. Following the completion of the transaction, the director directly owned 5,492,171 shares of the company’s stock, valued at approximately $11,808,167.65. This represents a 42.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cam Gallagher purchased 83,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were acquired at an average cost of $1.97 per share, with a total value of $163,510.00. Following the completion of the purchase, the director directly owned 83,000 shares in the company, valued at approximately $163,510. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 6.60% of the stock is owned by insiders.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.